Slider

Research strategy

Breadcrumb other pages

ERINHA has developed in 2017 its scientific strategy – a Research Portfolio, which is an evolving strategy built on the WHO Research and Development Blueprint with systematic updates to match with European and Global Research and Innovation and Public Health needs.

Current prioritized pathogens

    • Ebola,
    • Marburg,
    • Lassa,
    • Crimean-Congo Hemorrhagic Fever
    • Nipah/Hendra
    • Unknown agents
    • Bacteria

The table below presents ERINHA’s prioritized pathogens, built on the WHO R&D Blueprint:

The Agents Existing Diagnostics Prophylaxis Therapeutic interventions Mortality Rates
EBOLA Standardised molecular testing Clinical phase trials Clinical phase trials
MARBURG Standardised molecular testing No vaccine No therapeutic intervention
LASSA FEVER Standardised molecular testing No vaccine Ribavirin
CCHF
CRIMEAN-CONGO
Standardised molecular testing No vaccine No therapeutic
intervention
NIPAH/HENDRA No standardised
molecular
testing
Equine vaccine,
no human
vaccine
No therapeutic
intervention
UNKNOWN
AGENT
Tests not
produced yet
No vaccine No therapeutic
intervention
BACTERIA Standardised
molecular testing
Vaccine
prevalence
decreasing
Increasing
resistance to
therapeutics
*from Tuberculosis (TB)
REFERENCES
(1) Ebola virus disease Fact sheet, 2016, WHO, consulted from http://www.who.int/mediacentre/factsheets/fs103/en/
(2) Marburg haemorrhagic fever Fact Sheet, 2012, WHO, consulted from http://www.who.int/mediacentre/factsheets/fs_marburg/en/
(3) Lassa fever Fact Sheet, 2016, WHO, consulted from http://www.who.int/mediacentre/factsheets/fs179/en/
(4) Crimean-Congo haemorrhagic fever Fact Sheet, 2013, WHO, consulted from http://www.who.int/mediacentre/factsheets/fs208/en/
(5) Nipah virus outbreaks in the WHO South-East Asia Region, 2012, WHO consulted from http://www.searo.who.int/entity/emerging_diseases/links/nipah_virus_outbreaks_sear/en/
(6) Tuberculosis factsheet, 2017, WHO, consulted from http://www.who.int/mediacentre/factsheets/fs104/en/

FROM DISCOVERY TO PREVENTION – ERINHA’S RESEARCH APPROACH

Reinforcing European research capacities for global epidemics

O1 

PROVIDING DIAGNOSTIC CAPABILITIES

  • Maintain diagnostic pipeline for all newly identified agents of global concern
  • Share reagents and methods (collaborations with initiatives such as EVA-g)EQA schemes on developed diagnostics (through EMERGE)
  • Test rapid diagnostic provision capability
  • Increase epidemiological knowledge
  • Provision of diagnostics for field studies
  • Input from Academia and Industry on new diagnostic methods.
  • Sequencing and Bioinformatics
O2

INCREASING THE UNDERSTANDING OF THE DISEASE

  • Development of immunological tools for identification of correlate of protection discovery
  • Vaccine target discovery, development and efficacy testing capability using animal models
  • Therapeutic target discovery, development efficacy testing
  • Infection control practice development
03

DEVELOPING NEW INTERVENTIONS

  • In vitro modelling capability
  • Provide small animal models of infection
  • NHP modelling
  • Host animal modelling
  • Vector competence studies
  • Understanding blood chemistry
  • Modelling survival in body fluids (blood, urine, semen)
  • Modelling survival on surfaces
    environments
04

TRANSLATING INTERVENTION TO THE MARKET

  • GLP testing for intervention manufacturers
  • Analytical capability for clinical trials
  • Testing existing therapeutics against emerging agents
  • Efficacy data on disinfectant efficacy
  • Applied research on infection control

THE OUTPUTS

  • DIAGNOSTIC TOOLS
  • VACCINES
  • THERAPEUTICS
  • INCREASED KNOWLEDGE
  • EVIDENCE-BASED INFECTION CONTROL